Evidence map›Paper›PMID 39998341›Full record

Observational studyThe journal of ECT2025

Multicenter Observational Study of Electroconvulsive Therapy in Japan.

Takeshi Sakayori, Ken Wada, Minoru Takebayashi, Satoshi Ueda, Akihiko Machino, Atsushi Yoshimura, Enami Sawayama, Fumi Maruyama, Haruka Tanabe, Hidehiko Takahashi and 14 more

Abstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in The journal of ECT, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Takeshi SakayoriFrom the Department of Neuropsychiatry, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.
Ken WadaDepartment of Psychiatry, Hiroshima Citizens Hospital, Hiroshima City Hospital Organization, Hiroshima, Japan.
Minoru TakebayashiDepartment of Neuropsychiatry, Faculty of Life Science, Kumamoto University Hospital, Kumamoto, Japan.
Satoshi UedaFaculty of Medical Health, University of Tokyo Health Sciences, Tokyo, Japan.
Akihiko MachinoDivision of Psychiatry and Neuroscience, Institute for Clinical Research, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Hiroshima, Japan.
Atsushi YoshimuraDepartment of Psychiatry, Shiga University of Medical Sciences, Shiga, Japan.
Enami SawayamaDepartment of Psychiatry, Kitasato University School of Medicine, Kanagawa, Japan.
Fumi MaruyamaDepartment of Psychiatry, Suwa Red Cross Hospital, Nagano, Japan.
Haruka TanabeDepartment of Psychiatry, Shinshu University School of Medicine, Nagano, Japan.
Hidehiko TakahashiDepartment of Psychiatry and Behavioral Sciences, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.
Hideki AzumaDepartment of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Aichi, Japan.
Hiraki KoishikawaDepartment of Psychiatry and Psychosomatic Medicine, Kameda Medical Center, Japan.
Hiroki OzawaNeuropsychiatry, Medical, and Dental Sciences, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.
Kazuya OkuhiraDepartment of Neuropsychiatry, Wakayama Medical University, Wakayama, Japan.
Kazuyuki YasudaDepartment of Neuropsychiatry, University of Yamanashi Faculty of Medicine, Yamanashi, Japan.
Koichi MiyakawaJuntendo University School of Medicine, Juntendo University Urayasu Hospital Department of Psychiatry, Chiba, Japan.
Reiji YoshimuraDepartment of Psychiatry, University of Occupational and Environmental Health, Fukuoka, Japan.
Shigeru OzakiTokyo Metropolitan Toshima Hospital, Tokyo, Japan.
Shin YokoyamaPsychiatry, Nagano Red Cross Hospital, Nagano, Japan.
Shinkichi EtoDepartment of Psychiatry, Kamitsuga General Hospital, Tochigi, Japan.
Shoko TomonagaJR Tokyo General Hospital, Tokyo, Japan.
Shuichi IsomuraDivision of Neuropsychiatry, National Hospital Organization Kokura Medical Center, Fukuoka, Japan.
Tsukasa NonomuraChiba Aoba Municipal Hospital, Chiba, Japan.
Yoshiro OkuboFrom the Department of Neuropsychiatry, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe present study is the first large-scale, multicenter survey on modified electroconvulsive therapy (ECT) in Japan. We aimed to comprehend the current implementation status of ECT based on the annual reports of 2016 from 21 facilities that were certified by the Japanese Society of General Hospital Psychiatry as ECT certified facilities and participated in this multicenter observational study.

methodsWe investigated the distributions of diagnosis, gender, and age of patients receiving acute-phase ECT, and the efficacy, safety, and adverse events.

resultsThe number of patients receiving acute-phase ECT was 524. According to International Classification of Diseases, 10th Revision, 344 patients (65.6%) were diagnosed with mood disorders (F3), 156 patients (29.8%) were diagnosed with schizophrenia and with schizotypal and delusional disorders (F2), and 151 subjects were male and 334 subjects were female. The mean age of patients was 60.4 years (SD 15.9), and patients 60 years or older accounted for 57.9%. Efficacy did not significantly differ between diagnoses, nor between genders. However, the efficacy rate was significantly higher in elderly patients. In acute-phase ECT, 4 severe adverse events occurred.

conclusionsOur multicenter study confirmed that F3 (mood disorders) was the most common indication for ECT at 66%, followed by F2 (schizophrenia, schizotypal, and delusional disorders) at 30%, with no difference in efficacy, indicating that ECT is still performed as 1 of the treatment options for schizophrenia in Japan. The present results suggested that accumulation of annual data from multiple centers can be useful for more effective and safer ECT practices.

Indexed as

Electroconvulsive TherapyAdultAgedAged, 80 and overFemaleHumansJapanMaleMiddle AgedMood DisordersSchizophreniaTreatment OutcomeYoung Adult

Identifiers

PMID39998341
PMCPMC11895818

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.